Market capitalization | $2.15m |
Enterprise Value | $-1.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.15 |
P/B ratio (TTM) P/B ratio | 0.40 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-6.74m |
Free Cash Flow (TTM) Free Cash Flow | $-7.69m |
Cash position | $3.27m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
0%
0%
|
|
EBITDA | -6.73 -6.73 |
69%
69%
|
EBIT (Operating Income) EBIT | -6.74 -6.74 |
69%
69%
|
Net Profit | -6.46 -6.46 |
78%
78%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.
Head office | United States |
CEO | David Arthur |
Employees | 2 |
Founded | 2014 |
Website | salariuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.